Veru Inc Цена / балансовая стоимость

Что обозначает Цена / балансовая стоимость в Veru Inc?

Цена / балансовая стоимость Veru Inc является 23.71

Какое определение для Цена / балансовая стоимость?



Отношение рыночной цены акции к её балансовой учётной стоимости представляет собой соотношение между стоимостью акций компании и балансовой стоимостью на акцию.

The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).

The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).

P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.

Цена / балансовая стоимость компаний в Health Care сектор на NASDAQ по сравнению с Veru Inc

Что делает Veru Inc?

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries

Компании с цена / балансовая стоимость похож на Veru Inc



  • GT Biopharma имеет Цена / балансовая стоимость из 23.51
  • GlobalData Plc имеет Цена / балансовая стоимость из 23.54
  • Big Rock Partners Acquisition имеет Цена / балансовая стоимость из 23.54
  • Vivakor имеет Цена / балансовая стоимость из 23.57
  • Hambro Perks Acquisition имеет Цена / балансовая стоимость из 23.64
  • Daido имеет Цена / балансовая стоимость из 23.65
  • Veru Inc имеет Цена / балансовая стоимость из 23.71
  • Cub имеет Цена / балансовая стоимость из 23.72
  • Avricore Health имеет Цена / балансовая стоимость из 23.72
  • Automatic Data Processing имеет Цена / балансовая стоимость из 23.72
  • Tsakos Navigation имеет Цена / балансовая стоимость из 23.75
  • Inphi имеет Цена / балансовая стоимость из 23.82
  • Novo Nordisk имеет Цена / балансовая стоимость из 23.97